zzzs

Bio

Bio

Dr. Marmor is board certified in pulmonary and critical care medicine. She specializes in the treatment of individuals with chronic airway disease, bronchiectasis, and chronic lung infections.

Clinical Focus

  • Bronchiectasis
  • Airway Disease
  • Chronic Lung Infections
  • Critical Care Medicine

Academic Appointments

Professional Education

  • Board Certification: American Board of Internal Medicine, Critical Care Medicine (2019)
  • Fellowship: Stanford University Pulmonary and Critical Care Fellowship (2019) CA
  • Board Certification: American Board of Internal Medicine, Pulmonary Disease (2018)
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2016)
  • Residency: Brown University Internal Medicine Residency (2016) RI
  • Medical Education: University of Arizona College of Medicine Office of the Registrar (2013) AZ

Contact

  • Critical Care Medicine 300 Pasteur Dr Rm H2143 MC 5236 Stanford, CA 94305
    • Tel: (650) 723-6381
    Fax: (650) 725-5489

Publications

All Publications

  • Prolonged Hospitalization Following Acute Respiratory Failure. Chest Marmor, M., Liu, S., Long, J., Chertow, G. M., Rogers, A. J. 2020

    Abstract

    A better understanding of the clinical features associated with prolonged hospitalization in acute respiratory failure may allow for better informed care planning.To assess the incidence, mortality, cost and clinical determinants of prolonged hospitalization among patients with acute respiratory failure (ARF).Using the National Inpatient Sample (NIS) data from 2004 to 2014, we identified adults 18 years and older with International Classification of Disease, 9th Edition (ICD-9), codes for ARF requiring mechanical ventilation for at least two days (ICD-9 518.81 or 518.82, 96.7 or 96.04, and 96.05). Outcomes studied included incidence, in-hospital mortality, cost of hospitalization, and associated patient-level and hospital-level characteristics. Trends were assessed by logistic regression, linear regression and general linear modeling with Poisson distribution.Of the 5,539,567 patients with ARF, 77,665 (1.4%) had a prolonged length of stay, defined as ?60 days (pLOS). Among pLOS, 52,776 (68%) survived to discharge. Over the study period, incidence of pLOS decreased by 48%, in-patient mortality decreased by 18%, per patient cost-of-care rose, but percent of the total cost of ARF care consumed by patients with pLOS did not significantly decrease (p=0.06). PLOS was more likely to occur in urban teaching hospitals (OR 6.8, CI 4.6-10.2, p<0.001), hospitals located in the Northeastern US (OR 3.6, CI 3.0-4.3, p<0.001), and among patients with Medicaid insurance coverage (OR 2.1, CI 1.9-2.4, p<0.001).From 2004-2014, incidence and mortality decreased among patients with ARF and pLOS, and while per patient costs rose, percent of total cost of care remained stable. There is substantial variation in length-of-stay for patients with ARF by US region, hospital teaching status and patient insurance coverage.

    View details for DOI 10.1016/j.chest.2020.11.023

    View details for PubMedID 33333057

  • Corticosteroids for COVID-19-Associated ARDS Clinical Pulmonary Medicine Marmor, M. B., Jonas, A. M. 2020; 27 (6): 165-167

    View details for DOI 10.1097/CPM.0000000000000381

  • How is CF diagnosed? Facing Cystic Fibrosis: A Guide for Patients and Their Families Sher, Y. 2019
  • Opportunities to Improve Utilization of Palliative Care among Adults with Cystic Fibrosis: A Systematic Review. Journal of pain and symptom management Marmor, M., Jonas, A., Mirza, A., Rad, E., Wong, H., Aslakson, R. A. 2019

    Abstract

    Individuals with Cystic Fibrosis (CF) frequently survive into adulthood and many have multi-faceted symptoms that impair quality of life.We conducted a systematic review to investigate opportunities to improve utilization of palliative care among adults with CF.We searched PubMed, Embase, Scopus, Web of Science and CINAHL databases from inception until September 27, 2018, and reviewed references manually. Eligible articles were published in English, involved adults age 18 years and older with CF and contained original data regarding patient outcomes related to presence of advanced care planning (ACP), symptom experience, and preferred and/or received end-of-life care.We screened 652 article abstracts and 32 full text articles; 12 studies met inclusion criteria. All studies were published between 2000 and 2018. Pertinent findings include that while 43% to 65% of adults with CF had contemplated completing ACP, the majority only completed ACP during their terminal hospital admission. Patients also reported high prevalence of untreated symptoms, with adequate symptom control reported in 45% among those with dyspnea, 22% among those with pain and 51% among those with anxiety and/or depression. Prevalence of in-hospital death ranged from 62% to 100%, with a third dying in the intensive care unit (ICU). The majority received antibiotics and preventative treatments during their terminal hospitalization. Finally, treatment from a palliative care specialist was associated with a higher prevalence of patient completion of advanced directives, decreased likelihood of in-ICU death and decreased use of mechanical ventilation at end-of-life.Adults with CF often have untreated symptoms and many opportunities exist for palliative care specialists to improve ACP completion and quality of end-of-life care.

    View details for DOI 10.1016/j.jpainsymman.2019.08.017

    View details for PubMedID 31437475

Footer Links:

Stanford Medicine Resources: